Readoutin 14d
Sound Pharmaceuticals, Incorporated — Ebselen
Phase 3 primary completion: SPI-1005 for the Treatment of Meniere's Disease (Open Label).
- Date
- Dec 2026
- Type
- Readout
- Indication
- Meniere's Disease
Readoutin 14d
Phase 3 primary completion: SPI-1005 for the Treatment of Meniere's Disease (Open Label).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.